Targeting tumour vascularization from bench to bedside: Suggestions for combination with hyperthermia

Girolamo Ranieri, Annamaria Catino, Vittorio Mattioli, Vito Fazio, Gennaro Gadaleta-Caldarola, Cosmo Damiano Gadaleta

Research output: Chapter in Book/Report/Conference proceedingChapter


Angiogenesis is an important pathway in tumour growth and progression. Overexpression of pro-angiogenic factor or down regulation of physiologic angiogenic inhibitors are the stimuli that induce new blood vessel formation from a pre-existing vascular bed. On the other hand tumour vasculature is a major important factor influencing the therapeutic application of hyperthermia used as anticancer therapy. Both endothelial cells and microvessels can be lethally damaged by the hyperthermia. Because tumour vasculature is a target of hyperthermia combined treatments with angiogenesis inhibiting agents or vascular disrupting agents and hyperthermia may lead to synergetic effects or potentiation of the combined therapy over each modality alone. In this chapter we summarize the state of the art regarding the combination between drugs that targeting tumour vasculature and hyperthermia, furthermore the pre-clinical rationale for future clinical trials is suggested.

Original languageEnglish
Title of host publicationCancer Microenvironment and Therapeutic Implications: Tumor Pathophysiology Mechanisms and Therapeutic Strategies
PublisherSpringer Netherlands
Number of pages17
ISBN (Print)9781402095757
Publication statusPublished - 2009


  • Angiogenesis
  • Angiogenesis inhibiting agents
  • Clinical trials
  • Hyperthermia
  • Vascular disrupting agents

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Targeting tumour vascularization from bench to bedside: Suggestions for combination with hyperthermia'. Together they form a unique fingerprint.

Cite this